Can CAR-T keep up with the crowd?
If you haven’t been keeping up with Adam Feuerstein’s coverage of the American Society of Hematology meeting, here are two takeaways: CAR-T is doing wonders for patients with advanced blood cancer, and yet it’s possible those wonders could soon be overtaken.
That’s because amid all the positive CAR-T data, focused on lymphoma and myeloma, ASH also played host to some early but encouraging results from bispecific antibodies meant to turn the immune system’s attention on cancer. If those antibodies end up equaling or even besting CAR-T, they could upend the whole market. Crafting an antibody is considerably faster and less complicated than whipping up an engineered T cell, which means the bispecifics should be easier and less expensive once they're approved.
Bristol-Myers Squibb is one company that doesn’t have to choose between the two. Thanks to its recent acquisition of Celgene, the company has a pipeline of CAR-T’s and bispecifics alike, and “from the visibility that we have today,” Chief Medical Officer Dr. Samit Hirawat said, “I think we will need all of them.”
Read more.
That’s because amid all the positive CAR-T data, focused on lymphoma and myeloma, ASH also played host to some early but encouraging results from bispecific antibodies meant to turn the immune system’s attention on cancer. If those antibodies end up equaling or even besting CAR-T, they could upend the whole market. Crafting an antibody is considerably faster and less complicated than whipping up an engineered T cell, which means the bispecifics should be easier and less expensive once they're approved.
Bristol-Myers Squibb is one company that doesn’t have to choose between the two. Thanks to its recent acquisition of Celgene, the company has a pipeline of CAR-T’s and bispecifics alike, and “from the visibility that we have today,” Chief Medical Officer Dr. Samit Hirawat said, “I think we will need all of them.”
Read more.
No hay comentarios:
Publicar un comentario